40% of Medicinal Glass Will Be Upgraded to Medium Borosilicate Glass?

  Medicinal glass is one of the widely used pharmaceutical packaging materials for nitric acid. It can be divided into soda lime glass and borosilicate glass. Boron glass is divided into low borosilicate, medium borosilicate and high borosilicate glass.

  According to "China Pharmaceutical Glass Packaging Depth Research and Investment Strategy Report (2019 Edition)", the current domestic pharmaceutical glass products are still dominated by low borosilicate glass and soda lime glass.It is understood that low borosilicate glass is called "semi-neutral borosilicate medical glass", and its chemical stability is low. When a drug containes a high pH, the alkaline substance in the glass is easily precipitated and affects the quality of the drug. Most countries do not use it anymore.

  However, at present, most of the medicinal glass is still made of low borosilicate glass, so the total amount of medicinal glass is about 30, of which the amount of borosilicate used in 2018 is about 2.2~2.3, according to In terms of proportion, it is only about 7% to 8%. As the pharmaceutical packaging industry upstream of the pharmaceutical industry's industrial chain, the market scale has maintained a relatively high compound growth in the past five years. The Asia-Pacific market, which is dominated by China, has already surpassed Europe in size and it is approaching North America. However, behind the rapid growth, China's pharmaceutical packaging industry is large but not strong, the industry's overall added value is not high, the company is generally small in scale, low in technology, single in product structure, and the ratio of personnel, equipment and management comparing to mature markets in Europe and America. There is still a big gap.

  40% of medicinal glass or upgraded to medium borosilicate glass?


 

  For some reasons why it is not possible to produce high-quality and high-qualification medium-boron glass tubes. There are some analyses show that for a long time, high cost has hindered the popularization of neutral medicinal glass in China. In addition, the production stability of borax glass tubes is relatively high. Difficulty in control also resists the development of neutral medicinal glass to a certain extent.

  But drugs are a special kind of commodity that is directly related to the health and safety of consumers. Pharmaceutical packaging materials can be directly contacted with the drug, and its quality will affect the safety of the drug, the stability of the drug and the sale of the drug. Quickly achieve the stability of upgrading from low borosilicate glass to medium borosilicate glass.

  Initially stated, combined with the current Chinese policy and the concept of healthy China, pharmaceutical packaging is constantly upgrading, which will promote the upgrade of low borosilicate glass to borosilicate glass. According to forecasts, in the next 5 to 10 years, 30%-40% of China's pharmaceutical glass in the 1930s will be upgraded from low borosilicate glass to medium borosilicate glass.

  From the implementation of the policy, the implementation of important industrial policies such as “injection consistency evaluation” and “association assessment” will affect the future pattern, and the upgrade of low boron to medium boron is still an irreversible trend. Gradually carry out rapid advancing consistency evaluation, and related review and approval policies, which will effectively promote the upgrading of drug packaging materials and subsequent generic drugs, and the progress of neutral medicinal glass replacement is gradually accelerated. ”

  Taking Shandong Pharmaceutical Glass as an example, some research reports indicate that it is a domestic pharmaceutical glass leader, benefiting from the strict market share brought by strict drug safety supervision, the product upgrade revenue structure is continuously optimized, and revenue growth is stable; The scale and cost advantages are significant, and the potential is continuously tapped. The profitability is rising steadily and the performance is growing steadily.

  From 2014 to 2018, its operating income was 1.691 billion US dollars, 1.723 billion US dollars, 2.557 billion US dollars, 2.33 billion US dollars, and the performance of Shandong pharmaceutical glass business in the past five years can be seen, Shandong pharmaceutical glass performance shows steady growth situation. , 2.585 billion US dollars, respectively, 9.49%, 1.90%, 19.40%, 13.27%, 10.91%; net profit of the mother is 125 million, 145 million, 190 million, 263 million, 358 million, respectively It is 1.94%, 16.60%, 30.40%, 38.58%, and 36.33%.

  It is understood that the current domestic pharmaceutical glass market is nearly 10 billion, with an average annual growth rate of more than 10%. At present, there are more than 60 pharmaceutical glass production enterprises, mainly distributed in the southwest, east China, North China and other regions. The annual demand for products (molded bottles, controlled bottles, ampoules) is about 80 billion, of which about 15 billion are for molded bottles and controlled bottles, and nearly 40 billion for bottles.

  If you are interested in the Quartz Glass, Silk Screen Printed Glass, Quartz Glass Plate, Borosilicate Glass, or need to consult, please click on our online customer service or call us.

  Panshi customized different quality specifications of the glass.

  Panshi special industrial glass, tailored for your different quality of the glass.

  Welcome sending your inquiry: Phone : +8617656208428 Email: andy@quartzglassmade.com

Inquiry Details

Sales Manager: Amanda Hou

Email: amanda@biocryocontainer.com

Phone/WhatsApp: +8618937399428


Sales Manager: Andy Du

Email: andy@biocryocontainer.com

Phone/WhatsApp: +8617656208428


Company name: Xinxiang Panshi Instruments Co., Ltd.

Address: Room 1502, Jing Ye Gong Yuan Guo Ji, Jin Sui road and New Second Street intersection, Xin Xiang city, Henan Province, China